BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 22172829)

  • 1. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
    Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
    Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoral dose adjustment after conversion from C0 to C2 monitoring in stable renal transplant recipients: a prospective single center study.
    Sandrini S; Bossini N; Setti G; Mazzucchelli C; Maiorca P; Cancarini G
    J Nephrol; 2004; 17(2):284-90. PubMed ID: 15293530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.
    Li J; Dahmen U; Beckebaum S; Cicinnati V; Valentin-Gamazo C; Frilling A; Malago M; Broelsch CE
    Eur J Med Res; 2006 Apr; 11(4):139-45. PubMed ID: 16720277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
    J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
    Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE; Salmela KT
    Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R; Villafruela JJ; Pascual J; Teruel JL; Ocaña J; Tenorio MT; Burgos FJ; Ortuño J
    Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.
    Rostami Z; Einollahi B; Morshedi J; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):373-9. PubMed ID: 22976264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
    Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.